Literature DB >> 32501131

A de novo c.1509dupA:p.R503fs mutation of FUS: report of a girl with sporadic juvenile amyotrophic lateral sclerosis.

Li Chen1, Junmin Li1, Hong Lu1, Yanru Liu1.   

Abstract

Juvenile amyotrophic lateral sclerosis (JALS) is a rare and severe form of ALS. The development of sequencing methods has resulted in increased reports of JALS cases in recent years, this study, we identified a novel heterozygous mutation in exon 14, c.1509dupA:p.R503fs, of the RNA-binding protein fused in sarcoma (FUS) in a 17-year-old female patient with sporadic JALS who experienced rapid progression of muscular atrophy and died of respiratory failure 15 months after onset. Early onset, progressive muscular atrophy and weakness of the limbs with absence of intellectual impairment were the characteristics of this patient.

Entities:  

Keywords:  Juvenile amyotrophic lateral sclerosis; de novo mutation; fused in sarcoma (FUS); neurodegenerative disease; sporadic

Year:  2020        PMID: 32501131     DOI: 10.1080/21678421.2020.1775256

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  3 in total

1.  High-Throughput Genetic Testing in ALS: The Challenging Path of Variant Classification Considering the ACMG Guidelines.

Authors:  Serena Lattante; Giuseppe Marangi; Paolo Niccolò Doronzio; Amelia Conte; Giulia Bisogni; Marcella Zollino; Mario Sabatelli
Journal:  Genes (Basel)       Date:  2020-09-24       Impact factor: 4.096

2.  Sensitivity of Awaji Criteria and Revised El Escorial Criteria in the Diagnosis of Amyotrophic Lateral Sclerosis (ALS) at First Visit in a Tunisian Cohort.

Authors:  Bademain Jean Fabrice Ido; Imen Kacem; Mahamadi Ouedraogo; Amina Nasri; Saloua Mrabet; Amina Gargouri; Mouna Ben Djebara; Bawindsongré Jean Kabore; Riadh Gouider
Journal:  Neurol Res Int       Date:  2021-01-22

Review 3.  Juvenile Amyotrophic Lateral Sclerosis: A Review.

Authors:  Tanya Lehky; Christopher Grunseich
Journal:  Genes (Basel)       Date:  2021-11-30       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.